Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes

Starting soon

Conditions studied: Type 1 Diabetes Mellitus

In brief

To assess the real-world impact of glucose-lowering drugs (GLDs) as an adjunct to insulin in Chinese patients with type 1 diabetes (T1DM). Does glucose-lowering drugs (GLDs) as an adjunct to insulin improve clinical outcomes in Chinese patients with type 1 diabetes (T1DM) when used long-term in real-world practice?

Key facts

Study ID

NCT07415226

Run by

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

People needed

500

Starts

2026-05-01

Expected to finish

2027-12-31

Last updated by the study team

2026-02-17

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The research group consists of T1DM patients who first used oral hypoglycemic drugs from January 2013 to June 2024 and had a glycated hemoglobin level of >= 7%; The control group consisted of T1DM patients who maintained only insulin treatment regimen and had glycated hemoglobin >= 7%;
• Age >= 18 years old;
• At least one recorded HbA1c value before the start of treatment;
• Maintain medication regimen as needed from baseline to at least 3 months;
• Record the first glycated hemoglobin value after treatment.

You may not qualify if…

• The patient had already used hypoglycemic drugs as an adjunct to insulin therapy before admission;
• DKA、 Serious infection, perioperative status, severe trauma, pregnancy, patient's past or current involvement in interventional clinical research；
• The standard for determining stress hyperglycemia by the supervising physician;
• Patients who have no medication records or have not followed the treatment plan formulated by the doctor.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.